Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. (Q35989786)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539050%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

8 February 2021

comparative study

1 reference

PubMed publication ID

Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539050%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

13 December 2019

randomized controlled trial

1 reference

19 September 2019

humanized antibody

1 reference

27 September 2019

1 reference

12 November 2019

1 reference

21 December 2020

1 reference

8 February 2021

number needed to treat

1 reference

PubMed publication ID

zoledronic acid

1 reference

based on heuristic

inferred from title

Eleftheria Hatzimichael

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539050%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

George Dranitsaris

1

object named as

George Dranitsaris

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539050%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

27 April 2012

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539050%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 July 2012

2 references

21 December 2020

8 February 2021

Supportive Care in Cancer

10 references

13 March 2019

3 April 2019

19 September 2019

27 September 2019

12 November 2019

27 November 2019

13 December 2019

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539050%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

21 December 2020

8 February 2021

20

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539050%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539050%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1353-1360

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539050%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Advances in cancer therapeutics and patient access to new drugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

2 October 2017

Denosumab: the era of targeted therapies in bone metastatic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

2 October 2017

RANKL inhibition in the treatment of bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

2 October 2017

The cost of treating skeletal-related events in patients with prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

2 October 2017

Bisphosphonates for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

2 October 2017

Bisphosphonates: clinical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

2 October 2017

Mechanisms of bone metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

2 October 2017

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

2 October 2017

Understanding controlled trials: what outcomes should be measured?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

2 October 2017

Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

2 October 2017

Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

2 October 2017

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

11 July 2018

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

11 July 2018

Using numerical results from systematic reviews in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

11 July 2018

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

24 September 2018

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

24 September 2018

Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

24 September 2018

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360851

24 September 2018

Odds ratio, relative risk, absolute risk reduction, and the number needed to treat--which of these should we use?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22539050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22539050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current and future treatments of bone metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/22539050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value

1 reference

https://pubmed.ncbi.nlm.nih.gov/22539050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00520-012-1461-4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539050%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539050%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539050%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35989786&oldid=2198033364"